Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Note: Funding Information: 1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 2Department of Hematology, Amsterdam UMC, The Netherlands 3HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 4Department of Hematology, Amsterdam UMC, The Netherlands 5Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 6Department of Hematology, Isala Clinics, Zwolle, The Netherlands 7Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands 8Department of Hematology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands 9Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, University of Turin, Turin, Italy. This trial was supported by funding from Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors have indicated that they have no potential conflicts of interest to disclose. Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. HemaSphere (2020) 4:4(e370). http://dx.doi.org/10.1097/ HS9.0000000000000370. Received: 25 February 2020 / Accepted: 9 March 2020